^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    ACVR1 inhibitor

    Related drugs:
    2d
    ODYSSEY: Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis (clinicaltrials.gov)
    P2, N=68, Recruiting, GlaxoSmithKline | Trial completion date: Nov 2026 --> Mar 2028 | Trial primary completion date: Oct 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    Reblozyl (luspatercept-aamt) • Ojjaara (momelotinib)
    7d
    A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome (clinicaltrials.gov)
    P2, N=59, Recruiting, GlaxoSmithKline | N=45 --> 59
    Enrollment change
    |
    Ojjaara (momelotinib)
    7d
    RNA dicing promotes the expression of an oncogenic JAK1 isoform. (PubMed, Cell Rep)
    This results in a better response to the JAK1 inhibitor momelotinib, highlighting RNA dicing's role in patient stratification. Our findings show that RNA dicing diversifies mRNA products, significantly impacting biological functions.
    Journal
    |
    IFNG (Interferon, gamma) • JAK1 (Janus Kinase 1)
    |
    Ojjaara (momelotinib)
    14d
    A pharmacological profile of pacritinib for the treatment of myelofibrosis. (PubMed, Expert Rev Clin Pharmacol)
    While no JAK inhibitor has demonstrated clear disease-modifying effects in MF, pacritinib's non-myelosuppressive profile, unique activity against IRAK1, and potential anemia benefit via ACVR1 inhibition suggests potential utility as a backbone for future combination strategies. Ongoing and future studies will be critical to further define its role in phenotype-driven MF management.
    Review • Journal
    |
    JAK2 (Janus kinase 2) • JAK1 (Janus Kinase 1) • ACVR1 (Activin A Receptor Type 1) • IRAK1 (Interleukin 1 Receptor Associated Kinase 1)
    |
    Vonjo (pacritinib)
    21d
    FALKON: A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP). (clinicaltrials.gov)
    P2, N=113, Completed, Clementia Pharmaceuticals Inc. | Recruiting --> Completed
    Trial completion
    |
    ACVR1 (Activin A Receptor Type 1)
    26d
    Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts (clinicaltrials.gov)
    P4, N=268, Not yet recruiting, SWOG Cancer Research Network
    New P4 trial
    |
    Jakafi (ruxolitinib) • Ojjaara (momelotinib)
    26d
    M-HArbOr: Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia (clinicaltrials.gov)
    P1, N=18, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting --> Recruiting
    Enrollment open
    |
    azacitidine • Ojjaara (momelotinib)
    26d
    Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms (clinicaltrials.gov)
    P1/2, N=160, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Vonjo (pacritinib)
    1m
    A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) (clinicaltrials.gov)
    P2, N=78, Recruiting, Swedish Orphan Biovitrum | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Vonjo (pacritinib)
    2ms
    Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms (clinicaltrials.gov)
    P2, N=27, Recruiting, University of Washington | Not yet recruiting --> Recruiting
    Enrollment open
    |
    azacitidine • Inqovi (decitabine/cedazuridine) • Vonjo (pacritinib)
    2ms
    Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, United Lincolnshire Hospitals NHS Trust
    New P2 trial
    |
    Ojjaara (momelotinib) • bomedemstat (MK-3543)
    2ms
    GFM-VEXAS-MMB: Momelotinib in VEXAS syndrome (2024-519779-24-00)
    P1/2, N=57, Recruiting, Groupe Francophone Des Myelodysplasies
    New P1/2 trial
    |
    Ojjaara (momelotinib)